Saturday, March 18, 2017 2:51:56 AM
GILD has just started 2 trials in advance fibrosis and compensated cirrhosis named Stellar 3 and Stellar 4 respectively.
Stellar 3 has a key exclusion criteria a CP score >6 and Stellar 4 a CP score > 7 and any decompensation event. Basically it is positioning itself at the beginning of the spectrum of the sick patients , ie targeting Child Pugh A group in both cases , with 100% probability survival at 1 year.
CNAT is on the other hand targeting in ENCORE PH patients with HPVG > 12mmg and up to Child Pugh score of 10, which normally include up to MELD score to 15, ie compensated patients at high risk of developing decompensation or early decompensated.
In ENCORE LF it will be targeting decompensated patients with MELD score at or above 15, including also Child Pugh core C I assume.
From the above it is clear that CNAT Emricasan will be treating the sickest patients, and it does not have competition at the moment in this segment
https://www.researchgate.net/figure/6150278_fig1_Figure-1-Correlation-between-Child-Turcotte-Pugh-Child-and-model-for-end-stage-liver
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM